Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients

Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients

The Radiation Therapy Oncology Group (RTOG) 9310 protocol clinical trial established high-dose methotrexate (HDMTX) as the standard for primary central nervous system lymphoma (PCNSL). We aimed to investigate the RTOG 9310 protocol’s PCNSL outcomes by examining progression-free survival (PFS) and ov...

Full description

Bibliographic Details
Main Authors: Jinuk Kim, Tae Gyu Kim, Hyoun Wook Lee, Seok Hyun Kim, Ji Eun Park, Moonok Lee, Young Zoon Kim
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Current Oncology
Subjects:
adverse effect
chemotherapy
methotrexate
primary CNS lymphoma
prognosis
Online Access:https://www.mdpi.com/1718-7729/28/6/393

Internet

https://www.mdpi.com/1718-7729/28/6/393

Similar Items